CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 88 enrolled
Drug / intervention
AAB-003 (PF-05236812) +5 moredrug
Likely dose
AAB-003 (PF-05236812) 0.5 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01193608
NCT01193608Phase 1Completed
CompareCT.gov

A Phase 1, Multicenter, Randomized, Double-blind, Placebo-controlled, Adaptive, Multiple Ascending Dose Study Of The Safety, Tolerability And Pharmacokinetics Of Aab-003 (Pf-05236812) In Subjects With Mild To Moderate Alzheimer's Disease

Pfizer·interventional·Posted Sep 2, 2010·Updated Feb 23, 2017

In Brief

A Phase 1 clinical trial evaluating AAB-003 (PF-05236812) and Placebo for Alzheimer's Disease. Completed, enrolled 88 participants across 29 sites in 2 countries.

Detailed Summary

This is a study to evaluate the safety of multiple doses of AAB-003 (PF-05236812) in patients with mild to moderate Alzheimer's Disease. Patients will receive either AAB-003 (PF-05236812) or placebo. Each patient's participation will last approximately 41 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesSouth Korea, United States
CollaboratorsJANSSEN Alzheimer Immunotherapy Research & Development, LLC

Timeline

Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2, 2010
Enrollment StartSep 1, 2010
Primary CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 15.8 years ago

Interventions

AAB-003 (PF-05236812)drug

0.5 mg/kg AAB-003, IV

AAB-003 (PF-05236812)drug

1 mg/kg AAB-003, IV

AAB-003 (PF-05236812)drug

2 mg/kg AAB-003, IV

AAB-003 (PF-05236812)drug

4 mg/kg AAB-003, IV

AAB-003 (PF-05236812)drug

8 mg/kg AAB-003, IV

Placeboother

Placebo, IV